ACE inhibition and protection from doxorubicin-induced cardiotoxicity in the rat

Vascular Pharmacology

Volumn 50, Issue 5-6, 2009, Pages 166-170

  Sacco, Giuseppe ^a   Bigioni, Mario ^a   Lopez, Giuseppe ^a   Evangelista, Stefano ^a   Manzini, Stefano ^a   Maggi, Carlo Alberto ^a  

^a Menarini Ricerche ^*  (Italy)

Author keywords

Angiotensin converting enzyme (ACE); Anthracyclines; Cardioprotection; Electrocardiography; Lisinopril; Zofenopril

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; DOXORUBICIN; LISINOPRIL; ZOFENOPRIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; ELECTROCARDIOGRAPHY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME INHIBITION; HEART HEMODYNAMICS; HEART MUSCLE INJURY; HEART PROTECTION; MALE; NONHUMAN; PRIORITY JOURNAL; QT PROLONGATION; RAT;

ADMINISTRATION, ORAL; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CAPTOPRIL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG INTERACTIONS; ELECTROCARDIOGRAPHY; HEART; HEMODYNAMICS; LISINOPRIL; MALE; MYOCARDIUM; PEPTIDYL-DIPEPTIDASE A; RATS; RATS, WISTAR; TIME FACTORS;

EID: 61449181080     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2009.01.001     Document Type: Article

References (35)

1. Al-Shabannah O., Mansour M., El-Kashef H., and Al-Bekairi A. Captopril ameliorates myocardial and hematological toxicities induced by adriamycin. Biochem. Mol. Biol. 45 (1998) 419-427
2. Ambrosioni E., Borghi C., and Magnani B. The effect of the angiotensin converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N. Engl. J. Med. 332 (1995) 80-85
3. Boucek Jr. R.J., Steele A., Miracle A., and Atkinson J. Effect of angiotensin-converting-enzyme inhibitor on delayed-onset doxorubicin-induced cardiotoxicity. Cardiovasc. Toxicol. 3 (2003) 319-329
4. Buikema H., Monnink S.H., Tio R.A., Crijns H.J., De Zeeuw D., and Van Gilst W.H. Comparison of zofenopril and lisinopril to study the role of the sulphydryl-group in improvement of endothelial dysfunction with ACE-inhibitors in experimental heart failure. Br. J. Pharmacol. 130 (2000) 1999-2007
5. Chopra M., Beswick H., Clapperton M., Dargie H.J., Smith W.E., and Mc Murray J. Antioxidant effects of angiotensin-converting enzyme (ACE) inhibitors: free radical and oxidant scavenging are sulphydryl dependent, but lipid peroxidation is inhibited by both sulphydryl- and nonsulphydryl-containing ACE inhibitors. J. Cardiovasc. Pharmacol. 19 (1992) 330-340
6. Cirillo R., Sacco G., Venturella S., Brightwell J., Giachetti A., and Manzini S. Comparison of doxorubicin- and MEN 10755-induced long term progressive cardiotoxicity in the rat. J. Cardiovasc. Pharmacol. 35 (2000) 100-108
7. Cohn J.N. Reducing cardiovascular risk by blockade of the renin-angiotensin-aldosterone system. Adv. Ther. 24 (2007) 1290-1304
8. Cushman D.W., Wang F.L., Fung W.C., Grover G.J., Harvey C.M., Scalese R.J., Mitch S.L., and DeForrest J.M. Comparisons in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE). Br. J. Clin. Pharmacol. 28 suppl. 2 (1989) 115S-130S
9. Evangelista S., and Manzini S. Antioxidant and cardioprotective properties of the sulphydryl angiotensin-converting enzyme inhibitor zofenopril. J. Int. Med. Res. 33 (2005) 42-54
10. 14C-zofenopril, a new angiotensin converting enzyme inhibitor with high affinity for the tissues in rats. In: Pandalai S.G. (Ed). Recent Research Development in Drug Metabolism and Disposition. Trivandrum 1 (2000) 17-24
11. Ferrari R., Cargnoni A., Curello S., Ceconi C., Boraso A., and Visioli O. Protection of the ischemic myocardium by the converting-enzyme inhibitor zofenopril: insight into its mechanism of action. J. Cardiovasc. Pharmacol. 20 (1992) 694-704
12. Frascarelli S., Ghelardoni S., Ronca-Testoni S., and Zucchi R. Cardioprotective effect of zofenoprilat in perfused rat heart subjected to ischemia and reperfusion. J. Cardiovasc. Pharmacol. 43 (2004) 294-299
13. Fratta Pasini A., Garbin U., and Nava M.C. Effect of sulfhydryl and non-sulfhydryl angiotensin converting-enzyme inhibitors on endothelial function in hypertensive patients. Am. J. Hypertens. 20 (2007) 443-450
14. Jensen R.A., Acton E.M., and Peters J.H. Doxorubicin cardiotoxicity in the rat: comparison of electrocardiogram, transmembrane potential, and structural effects. J. Cardiovasc. Pharmacol. 6 (1984) 186-200
15. Keizer H.G., Pinedo H.M., Schuurhuis G.J., and Joenje H. Doxorubicin (adriamycin), a critical review of free radical dependent mechanism of citotoxicity. Pharmacol. Ther. 47 (1990) 219-231
16. Kusuoka H., Futaki S., Koretsune Y., Kitabatake A., Suga H., Kamada T., and Inoue M. Alterations of intracellular calcium homeostasis and myocardial energetics in acute adriamycin-induced heart failure. J. Cardiovasc. Pharmacol. 18 (1991) 437-444
17. Yin X., WU H., Chen Y., and Kang Y.J. Induction of antioxidants by adriamycin in mouse heart. Biochem. Pharmacol. 56 (1998) 87-93
18. Li K., and Chen X. Protective effects of captopril and enalapril on myocardial ischemia and reperfusion damage of rat. J. Mol. Cell Cardiol. 19 (1987) 909-915
19. Li T., Danelisen I., Bello-Klein A., and Singal P.K. Effects of probucol on changes of antioxidant enzymes in adriamycin-induced cardiomyopathy in rats. Cardiovasc. Res. 46 (2000) 523-530
20. Liu X., Engelman R.M., Rousou J.A., Cordis G.A., and Das D.K. Attenuation of myocardial reperfusion injury by sulphydryl-containing angiotensin converting enzyme inhibitors. Cardiovasc. Drugs Ther. 6 (1992) 437-443
21. Maeda A., Honda M., Kuramochi T., Tanaka K., and Takabatake T. An angiotensin-converting enzyme inhibitor protects against doxorubicin-induced impairment of calcium handling in neonatal rat cardiac myocytes. Clin. Exp. Pharmacol. Physiol. 24 (1997) 720-726
22. Mak I.T., Freedman A.M., Dickens B.F., and Weglicki W.B. Protective effects of sulphydryl-containing enzyme inhibitors against free radical injury in endothelial cells. Biochem. Pharmacol. 40 (1990) 2169-2175
23. Minotti G., Cavaliere A.F., Mordente A., Rossi M., Schiavello R., Zamparelli R., and Possati G.F. Secondary alcohol metabolites mediate iron delocalization in cytosolic fractions of myocardial biopsies exposed to anticancer anthracyclines - novel linkage between anthracycline metabolism and iron-induced cardiotoxicity. J. Clin. Invest. 95 (1995) 1595-1605
24. Minotti G., Menna P., Salvatorelli E., Cairo G., and Gianni L. Anthracyclines: molecular advances and pharmacological developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 56 (2004) 185-229
25. Node K., Kitakaze M., Kosaka H., Minamino T., Mori H., and Hori M. Role of Ca++-activated K+ channels in the protective effect of ACE inhibition against ischemic myocardial injury. Hypertension 31 (1998) 1290-1298
26. Oliveira E.M., Santos R.A.S., and Krieger J.E. Standardization of a fluorimetric assay for the determination of tissue angiotensin-converting enzyme activity in rats. Braz. J. Med. Biol. Res. 33 (2000) 755-764
27. Olson D.R., and Mushlin P.S. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J. 4 (1990) 3076-3086
28. Pessah I.N., Schiedt M.J., Shalaby M.A., Mack M., and Giri S.N. Etiology of sarcoplasmic reticulum calcium release channel lesions in doxorubicin-induced cardiomyopathy. Toxicology 72 (1992) 189-206
29. Rhoden W., Hasleton P., and Brooks N. Anthracyclines and the heart. Br. Heart J. 70 (1993) 499-502
30. Robert J. Preclinical assessment of anthracycline cardiotoxicity in laboratory animals: predictiveness and pitfalls. Cell Biol. Toxicol. 23 (2007) 27-37
31. Sacco G., Bigioni M., Evangelista S., Cristina G., Manzini S., and Maggi C.A. Cardioprotective effects of zofenopril, a new angiotensin-converting enzyme inhibitor, on doxorubicin-induced cardiotoxicity in the rat. Eur. J. Pharmacol. 414 (2001) 71-78
32. Santos R.A.S., Krieger E.M., and Greene L.J. An improved fluorometric assay of rat serum and plasma converting enzyme. Hypertension 7 (1985) 244-252
33. Sun Y., and Mendelsohn A.O.F. Angiotensin converting enzyme inhibition in heart, kidney, and serum studied ex vivo after administration of zofenopril, captopril, and lisinopril. J. Cardiovasc. Pharmacol. 18 (1991) 478-486
34. Tokudome T., Mizushige K., Noma T., Manabe K., Murakami K., Tsuji T., Nozaki S., Tomohiro A., and Matsuo H. Prevention of doxorubicin (adriamycin)-induced cardiomyopathy by simultaneous administration of angiotensin-converting enzyme inhibitor assessed by acoustic densitometry. J. Cardiovasc. Pharmacol. 36 (2000) 361-368
35. Villani F., Monti E., Piccinini F., Favalli L., Lanza E., Rozza Dionigi A., and Poggi P. Relationship between doxorubicin-induced ECG changes and myocardial alterations in rats. Tumori 72 (1986) 323-329